A Phase 3 interventional study of Sotatercept in Pulmonary Arterial Hypertension, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 137 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing sotatercept in Pulmonary Arterial Hypertension — 7 open to participants now, 10 under way, 1 of them phase 3. sotatercept · Pulmonary Arterial Hypertension.
Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, this one has the largest planned enrollment, is one of 3 that started in 2021, is one of 5 in phase 3, and was the 14th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →7 of the 18 studies testing sotatercept in Pulmonary Arterial Hypertension are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in India
Ages 18+
Merck Sharp & Dohme LLC · Sites in Japan
Ages 1–17
Kazuya Hosokawa · Sites in Japan
Ages 18+
Amsterdam UMC, location VUmc · Sites in Netherlands
Ages 18–70
Merck Sharp & Dohme LLC · Sites in United States, Australia, Colombia and 9 more countries
Ages 1–17
By country, each count listing its studies:
sotatercept: first FDA approval 2024 (WINREVAIR), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 3 started in 2021.
This study's planned enrollment of 815 is above the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 44 across the 18 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc: 3 open now, 5 under way, 1 of them phase 3. Of 12 finished, 11 (92%) have results posted.
Among the 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc, this one has the largest planned enrollment, is one of 4 that started in 2021, is one of 5 in phase 3, and was the 15th registered.
Merck & Co., Inc’s Pulmonary Arterial Hypertension studies by the year they started, since 2013.
1 of the studies testing sotatercept in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07356778Kazuya HosokawaA Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy | 2027-08-31 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, from their registry updates:
Among Merck & Co., Inc’s 17 in Pulmonary Arterial Hypertension:
This tab as a report to print or save as PDF → With an account.
Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart. PAH can make it hard to breathe and be active. Some standard (usual) treatments for PAH can treat symptoms of PAH but do not stop PAH from getting worse.
Sotatercept is a study medicine designed to treat PAH. It is a targeted therapy, which is a treatment that works on certain proteins that play a role in causing PAH.
This is a long-term follow-up (LTFU) study. People who took part in certain other studies testing sotatercept for PAH may be able to join this study. The goal of this study is to learn about the long-term safety of sotatercept and if people tolerate it when taken with standard PAH treatment over a longer period of time.
LTFU PAH sotatercept study MK-7962-004 (Obsolete Identifier: NCT04796337) has been incorporated into the current MK-7962-038 (NCT07218029) study for administrative reasons. The MK-7962-004 study is no longer enrolling participants and will be formally closed. Only those who participated in MK-7962-004 may be eligible to continue into MK-7962-038.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants enrolling from blinded PAH sotatercept studies will begin sotatercept at a dose of 0.3 mg/kg subcutaneous (SC) injection and can titrate up to the target dose of 0.7 mg/kg SC injection for the remainder of the study. Participants enrolling from unblinded PAH sotatercept studies will continue sotatercept at their current dose and, if at a dose \<0.7 mg/kg, can titrate up to the target dose of 0.7 mg/kg SC injection for the remainder of the study.
Biological: Sotatercept
Sotatercept SC injection every 3 weeks
Also known as: MK-7962, ACE-011, ActRIIA-IgG1Fc, WINREVAIR®
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 90 months
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately 86 months
Number of Participants with Detectable Anti-Drug Antibodies (ADAs)
ADAs will be detected in serum. The number of participants with detectable ADAs will be reported.
Time frame: Up to approximately 88 months
Laboratory parameters (Hematology): Concentration of Platelets and Hemoglobin
Blood samples will be collected to determine the concentration of platelets and hemoglobin.
Time frame: Up to approximately 88 months
Laboratory parameters (Chemistry): Concentration of Creatinine, Total Bilirubin, and Alanine Aminotransferase (ALT)
Blood samples will be collected to determine the concentration of creatinine, total bilirubin, and ALT.
Time frame: Up to approximately 86 months
Change From Baseline in Body Weight
Change from baseline in body weight will be reported.
Time frame: Baseline and up to approximately 86 months
Change From Baseline in Blood Pressure
Change from baseline in systolic and diastolic blood pressure will be reported.
Time frame: Baseline and up to approximately 86 months
Change From Baseline in Electrocardiogram (ECG)
Change from baseline in ECG (12-lead) for the determination of Fridericia's corrected QT interval (QTcF) will be reported.
Time frame: Baseline and up to approximately 86 months
Change From Baseline in 6-Minute Walk Distance (6MWD)
The 6MWD is the distance walked in 6 minutes as a measure of functional capacity. The change from baseline in 6MWD will be reported.
Time frame: Baseline and up to approximately 48 months
Change From Baseline in N-Terminal Pro-Hormone B-type Natriuretic Peptide (NT-proBNP) Levels
NT-proBNP is a circulating biomarker that reflects myocardial stretch. The change from baseline in NT-proBNP levels will be reported.
Time frame: Baseline and up to approximately 48 months
Change From Baseline in the Percentage of Participants Who Improve or Show Maintenance in Modified New York Heart Association/ World Health Organization Classification of Functional Status (WHO FC)
The severity of participant's PAH symptoms will be graded using the WHO FC system. WHO functional classification for PAH ranges from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform physical activity without any symptoms, dyspnea at rest). Participants will be classified as "Improved", "No change", or "Worsened". Improved = reduction in WHO FC; No Change = no change in WHO FC; Worsened = increase in WHO FC. The change from baseline in the percentage of participants who improve or show maintenance in WHO FC will be reported.
Time frame: Baseline and up to approximately 48 months
Change From Baseline in Pulmonary Vascular Resistance (PVR)
PVR is a hemodynamic variable of pulmonary circulation and is measured by right heart catheterization. The change from baseline in PVR will be reported.
Time frame: Baseline and up to approximately 48 months
Change From Baseline in Percentage of Participants Who Maintain or Achieve a Low Risk Score Using the Simplified French Risk Score Calculator
The simplified French Risk scoring system is based on the 2015 European Society of Cardiology/European Respiratory Society guidelines for the diagnosis and treatment of pulmonary hypertension (PH). Noninvasive parameters (WHO FC, 6MWD, NT-proBNP levels) will be used to determine the score. 'Low risk' is defined as maintaining or achieving all 3 low-risk criteria: WHO FC I or II, 6MWD \>440 meters, and NT-proBNP \<300 ng/L. The change from baseline in percentage of participants who maintain or achieve a low risk simplified French Risk score will be reported.
Time frame: Baseline and up to approximately 48 months
Showing the first 100 of 137 sites across 27 countries. Choose a country and city above to see the rest.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Started May 2021 (actual). Primary completion is estimated for Dec 2028, 90 months after the start.
Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's planned 90 months is above that.
Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotatercept
Pulmonary Arterial Hypertension →